drugset

drugset / Trial / NCT00646191

Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00646191 ↗

Phase 2 Completed 137 enrolled Abbott

RandomizedParallel-groupDouble-blindTreatment

Summary

Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis

Timeline

Start: 2003-03
Primary completion: 2004-06
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Adalimumab	Monoclonal antibody	40 mg	—

Indications